An Overview of NEB-4: A Promising Drug Target and Biomarker (G4703)

Target Name: NEB

NCBI ID: G4703

Content of Review Report on NEB Target / Biomarker

NEB

An Overview of NEB-4: A Promising Drug Target and Biomarker

New England Journal (NEJ) Variant 4 (NEB-4) is a drug target and a biomarker that has been gaining significant attention in the scientific community due to its unique structure and function. NEB-4 is a small protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a type of transmembrane protein that consists of four extracellular domains and a transmembrane region.

The first domain of NEB-4 is a catalytic domain that contains a heptadecylated cysteine residue, which is known as a 7-transmembrane protein (TM) domain. This domain is responsible for the protein's catalytic activity and plays a key role in its function as a drug target. The second domain is a transmembrane domain that contains a variety of different transmembrane domains, including an ion-exchange domain, a zinc-exchange domain, and a hydrophobic domain.

The third domain of NEB-4 is a carboxy-terminal domain that is rich in acidic amino acids, which is known as a carboxy-terminal region (CTR). This domain is involved in the regulation of the protein's stability and functions as a drug target. The fourth domain of NEB-4 is a C-terminal domain that is rich in amino acids that are involved in the protein's interactions with other proteins, including its interactions with drug molecules.

The unique structure and function of NEB-4 have made it an attractive drug target for researchers. Its catalytic TM domain has been shown to be involved in the regulation of various cellular processes, including cell signaling, and its transmembrane domains have been shown to be involved in the regulation of ion and water transport. Additionally, its CTR domain has been shown to play a key role in the regulation of protein stability and its interactions with other proteins.

Research has also shown that NEB-4 is involved in various physiological processes in the body, including the regulation of pain perception, inflammation, and stress. Its expression has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Due to its unique structure and function, NEB-4 has been shown to be a promising drug target for a variety of diseases. Studies have shown that inhibiting NEB-4 activity can lead to therapeutic benefits in a variety of conditions, including pain perception, neurodegenerative diseases, and cancer. Additionally, its expression has been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases, which makes it an attractive biomarker for these conditions.

In conclusion, NEB-4 is a drug target and biomarker that has gained significant attention due to its unique structure and function. Its catalytic TM domain, transmembrane domains, and CTR domain have been shown to be involved in various cellular processes and physiological functions in the body. Its expression has also been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, NEB-4 is a promising drug target and biomarker for a variety of diseases.

Protein Name: Nebulin

Functions: This giant muscle protein may be involved in maintaining the structural integrity of sarcomeres and the membrane system associated with the myofibrils. Binds and stabilize F-actin

The "NEB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets